INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. Patients with high-risk disease manifest by del17(p13.1), p53 mutation, complex karyotype, or unmutated immunoglobulin variable regions require earlier therapy and have shorter survival. [1] [2] [3] For patients able to tolerate aggressive therapy, chemo-immunotherapy has been the preferred approach 4 ; however, recently, the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, was approved, initially for relapsed and refractory disease and subsequently for firstline therapy. 5, 6 Although the overall response rate (ORR) to ibrutinib is high, the complete response (CR) rate is low, and survival of patients who experienced progression while receiving ibrutinib is short, with one study reporting median overall survival (OS) of only 3 months. 7, 8 The BCL2 inhibitor, venetoclax, has shown activity in some patients who experienced treatment failure with ibrutinib therapy, but CR is rare and durability not reported.
Lymphodepletion chemotherapy followed by CD19-specific chimeric antigen receptor-modified T (CAR-T) cell infusion has produced high response rates in patients with refractory B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). [10] [11] [12] [13] [14] [15] [16] In a small study, CD19 CAR-T cells induced durable remissions in a subset of patients with CLL, few of whom had previously received ibrutinib.
14, 17 Here, we report a high rate of elimination of marrow disease and molecular CR in patients with high-risk ibrutinib-refractory CLL after lymphodepletion and CD19-targeted CAR-T cell therapy.
METHODS

Study Design and Patient Selection
We performed a phase I/II open-label clinical trial with the primary objective of evaluating the feasibility and safety of infusing a defined composition of CD4 + and CD8 + CD19-specific CAR-T cells after lymphodepletion chemotherapy in patients with relapsed or refractory CD19 + B-cell malignancies (Appendix, online only). CAR-T cells were administered at dose level (DL) 1 (2 3 10 5 CAR-T cells/kg), DL2 (2 3 10 6 CAR-T cells/kg), or DL3 (2 3 10 7 CAR-T cells/kg), and a 3 + 3 design was used to establish a maximum tolerated dose of CAR-T cells in each disease cohort. The study was conducted with informed consent and approval of the Fred Hutchinson Cancer Research Center institutional review board. Patients with CLL were eligible if they had experienced treatment failure after receiving an anti-CD20 antibody and fludarabine (Flu) or bendamustine. This article reports the outcome of patients with CLL, all of whom had previously received ibrutinib, treated in the study before September 2016.
Lymphodepletion Chemotherapy and CAR-T Cell Manufacturing and Infusion
Peripheral blood mononuclear cells were collected by leukapheresis for manufacturing CAR-T cells as described. 15, 16 Autologous CD4 + and either bulk or central memory (T CM )-enriched CD8 + T cells were immunomagnetically selected and then modified with a lentivirus encoding a chimeric antigen receptor comprising a CD19-specific scFv, IgG4-hinge, CD28 transmembrane domain, and 4-1BB and CD3z signaling domains. The chimeric antigen receptor was separated by a ribosomal skip sequence from a truncated human epidermal growth factor receptor (EGFRt), which enabled CAR-T cell enumeration by flow cytometry and formulation of a 1:1 CD4 + :CD8
+ CAR-T cell ratio for infusion. CAR-T cells were administered after lymphodepletion chemotherapy consisting of cyclophosphamide (Cy), Flu, or Cy plus Flu.
Clinical Response Assessment
Patients underwent whole-body imaging with a diagnostic-quality computed tomography (CT) scan before and 4 weeks after CAR-T cell administration. Nodal responses are reported by International Workshop on Chronic Lymphocytic Leukemia (IWCLL; 2008) criteria, and when positron emission tomography (PET) imaging was available, by Cheson 2014 criteria (Appendix).
18,19 Marrow biopsies were obtained before lymphodepletion and 4 weeks after administration of CAR-T cells. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (version 4.03), with the exception of cytokine release syndrome (CRS), which was graded as described. 20 Neurotoxicity did not contribute to organ toxicity in CRS grading.
Cytokine Assay
Serum cytokine concentrations were evaluated by Luminex assay (Luminex Corporation, Austin, TX) according to the manufacturer's instructions.
BTK and PLCG2 Mutation Analyses
Peripheral blood mononuclear cells or marrow samples collected before lymphodepletion were sequenced without B cell selection to detect BTK or PLCG2 mutations, as described.
21,22
Statistical Analysis
The statistical analyses are described in the Appendix.
RESULTS
Patient Characteristics
Thirty patients underwent screening and leukapheresis (Table 1) . Five patients were responding to or had not received ibrutinib and did not proceed to lymphodepletion and CAR-T cell infusion, and one ibrutinib-refractory patient became ineligible for study treatment. Twenty-four patients (median age, 61 years; range, 40-73 years) who had received a median of five previous therapies (range, 3-9) received lymphodepletion followed by CD19 CAR-T cell infusion. All patients had highrisk disease, with 96% having high-risk cytogenetics. The median percentage of marrow abnormal B cells before lymphodepletion chemotherapy was 61.6% (range, 0%-96%). Twenty-three patients had nodal disease, and two had active CNS disease. Fourteen of 15 patients who had measurable disease by CT and underwent PET imaging had [
18 F]fluorodeoxyglucose (FDG)-avid disease.
Twenty-three of 24 patients were refractory to or had relapsed after a regimen containing Flu and rituximab; one patient who received bendamustine plus rituximab experienced treatment failure. All patients had received ibrutinib (median duration, 13 months; range, 0.75-39 months). Nineteen patients experienced disease progression while receiving ibrutinib, and three were ibrutinib intolerant. Ibrutinib was discontinued in all patients before lymphodepletion, including two who had not experienced disease progression while receiving ibrutinib because the safety of concurrent CAR-T cells and ibrutinib had not been established. Mutations associated with ibrutinib resistance were detected in nine of 19 patients (47%; BTK, n = 7; PLCG2, n = 2). Six patients had received venetoclax, and all were refractory. During the 3 weeks between leukapheresis and lymphodepletion, six patients required high-dose corticosteroids to control progressive disease, and two others required treatment of tumorassociated hypercalcemia.
Lymphodepletion and CD19 CAR-T Cell Infusion
Lymphodepletion regimens are listed in Table 2 . CD19 CAR-T cells were formulated for infusion by combining CD4 + CAR-T cells with CAR-T cells manufactured from the CD8 + T CM subset (n = 7) or bulk CD8 + T cells (n = 17). A CAR-T cell product was manufactured for all patients, and 22 of 24 patients received CD4 + and CD8
+ CAR-T cells in the prescribed 1:1 ratio; two patients received less than the target CD8 + CAR-T cell dose (58.5% and 56.3%). Four patients received DL1, 19 received DL2, and one received DL3 (Table 2 ). Six patients with persistent or relapsed disease after initial restaging received a second cycle of lymphodepletion and CAR-T cell infusion. kDied of toxicity before restaging. ¶Also received siltuximab 11 mg/kg IV. #Restaging 8 weeks later without additional antitumor therapy showed no FDG-avid disease and PR (maximum node 16 mm) on CT.
CD19 CAR-T Cell Expansion and Persistence
We detected CAR-T cells by flow cytometry in blood obtained after infusion in all patients. We observed a direct correlation between peak in vivo CAR-T cell frequency and the absolute abnormal B cell count in blood, the percentage of marrow abnormal B cells, and the tumor cross-sectional area before lymphodepletion (Figs 1A, 1B, and 1C) and an inverse correlation between CAR-T cell expansion and the maximum standardized uptake value in those with FDG-avid disease on pretreatment PET scans (Fig 1D) . CAR-T cells were detected by quantitative polymerase chain reaction in blood at $ 6 months in all patients (n = 11) who were evaluated and did not undergo subsequent allogeneic hematopoietic stem cell transplantation.
Toxicity Assessment Following CD19 CAR-T Cell Therapy in Patients With CLL
A majority of patients developed toxicities expected with lymphodepletion chemotherapy. A total of 20 of 24 had CRS. Eighteen of 24 had grade 1-2 CRS. One of 24 had grade 4 CRS. One of 24 had grade 5 CRS. However, clinical symptoms were sufficiently severe to require tocilizumab and corticosteroid treatment in only six of 24 patients (25%; Table 2 ; Appendix). A total of eight of 24 had neurotoxicity. Two of 24 had grade 1-2 neurotoxicity. Five of 24 had grade 3 neurotoxicity. One of 24 had grade 5 neurotoxicity. All patients with neurotoxicity also had CRS. Two patients required intensive care unit management, and one of these developed fatal neurotoxicity after infusion of 2 3 10 6 CAR-T cells/kg. Neurotoxicity was reversible in all other patients. One patient who had previously received alemtuzumab, Flu, and rituximab developed late John Cunningham (JC) virus-positive progressive multifocal leukoencephalopathy, which was considered unrelated to CAR-T cell therapy. The median duration of all-cause hospitalization was 9 days (range, 0-49 days). We previously reported that the infusion of 2 3 10 7 CAR-T cells/kg after Cy plus Flu lymphodepletion was excessively toxic in patients with ALL and NHL 15, 16 ; therefore, after one patient with CLL developed grade 4 CRS and grade 3 neurotoxicity after receiving 2 3 10 7 CAR-T cells/kg, we selected a maximum dose of 2 3 10 6 CAR-T cells/kg for subsequent patients with CLL (Appendix).
Factors Correlating With Cytokine Release Syndrome and Neurotoxicity
CRS is initiated by activation and proliferation of CAR-T cells after CD19
+ target cell recognition. The percentage of leukemic B cells in marrow before therapy was higher in patients who developed CRS and neurotoxicity compared with those who did not (CRS grade 0 v grade 1-5; median, 1.8% v 65.5%; P = .035; neurotoxicity, grade 0 v grade 1-5; 36.7% v 77.5%; P = .13). Peak CD4 + and CD8 + CAR-T cell numbers in blood after infusion were higher in patients with grade 1 to 3 CRS and grade 1 to 3 neurotoxicity, compared with those without CRS or neurotoxicity, but were not higher in patients with grade 4 to 5 toxicity, potentially a result of high-dose corticosteroids administered to treat serious toxicity (Figs 2A and 2B) .
Peak serum concentrations of distinct cytokines, ferritin, and C-reactive protein after CAR-T cell infusion differed in patients jco.org with grade 2 to 5 CRS or neurotoxicity compared with those with grade 0 to 1 CRS or neurotoxicity (Figs 2C and 2D) . We evaluated serum biomarkers in the first 48 hours after CAR-T cell infusion to determine whether patients at highest risk for more severe neurotoxicity might be identified for early intervention. In univariable analyses, we found higher interferon-gamma and interleukin-10 in the first 48 hours after CAR-T cell infusion in patients who subsequently developed grade $ 2 neurotoxicity (Fig 2E) . Interferongamma (P = .034) and interleukin-10 (P = .045) remained associated in stepwise multivariable regression analysis.
High Lymph Node Response Rate in High-Risk CLL
Twenty-four patients received lymphodepletion and CAR-T cells. The ORR by IWCLL criteria 4 weeks after CAR-T cell infusion was 71% (17 of 24 patients). One patient developed fatal neurotoxicity and did not undergo response assessment. Among the 23 restaged patients, the ORR at 4 weeks after CAR-T cell infusion by IWCLL lymph node criteria was 70% (16 of 23 patients). One additional patient achieved a late response. During the course of this study, data in ALL and NHL demonstrated superior response rates in patients who received CAR-T cells after Cy/Flu compared with Flu lymphodepletion.
15,16 Three patients with CLL did not receive Cy plus Flu lymphodepletion, and only one patient cleared marrow disease, one had a partial response (PR; IWCLL imaging criteria), and all developed progressive disease. Although the study was not powered to determine the optimal regimen, our preferred lymphodepletion regimen contains both Cy and Flu (Appendix).
Twenty patients received Cy plus Flu lymphodepletion and a single CD19 CAR-T cell infusion at or below the maximum tolerated dose (# 2 3 10 6 CAR-T cells/kg). In 19 restaged patients, we identified a lymph node response by IWCLL criteria in 14 of 19 patients, 74%, 95% CI, 49% to 91%; CR, four of 19, 21%; PR, 10 of 19, 53%. Response rates were similar in the 16 ibrutinib-refractory patients included in this subgroup treated with Cy plus Flu and # 2 3 10 6 CAR-T cells/kg with an ORR in 11 of 16 patients, 69%, 95% CI, 41% to 89%; and CR in four of 16 patients, 25%. A lymph node response (CR or PR by IWCLL) was associated with longer progression-free survival (PFS) and OS compared with those who experienced treatment failure (stable disease or progressive disease), and patients who achieved PR by IWCLL criteria did not have inferior PFS and OS compared with those who achieved CR ( Figs 3A and 3B) . The PFS and OS for all patients with CLL are shown in Appendix Figure A1 (online only). No responding patients underwent hematopoietic stem cell transplantation after receiving CAR-T cells.
Because study participants had highly aggressive disease, where feasible, we also assessed the lymph node response by PET imaging 4 weeks after CAR-T cell infusion. The CR rate using PET-CT restaging observed in seven of 11 patients (64%, 95% CI, 31% to 89%; Deauville score, 1-2) was higher than that observed after restaging by IWCLL (four of 19 patients, 21%, 95% CI, 6% to 46%). Four of five patients (80%) classified as PR by IWCLL had no FDG-avid disease by PET imaging after CAR-T cell immunotherapy, and an additional patient with stable disease on PET-CT at 4 weeks subsequently achieved CR on follow-up PET-CT 8 weeks later.
High Rate of Elimination of Malignant IGH Sequences From Marrow
Twenty-two of 24 patients had marrow disease before treatment, and 21 patients had a bone marrow evaluation 4 weeks after CAR-T cells. Seventeen of 21 patients (81%) had no marrow disease detected by high-resolution flow cytometry. Fifteen of 17 patients (88%, 95% CI, 64% to 99%) with marrow involvement before therapy and who received Cy plus Flu lymphodepletion and # 2 3 10 6 CAR-T cells/kg eliminated CLL from marrow by flow cytometry. 18 The flow-negative marrow response rate in the subset of ibrutinib-refractory patients who received the same treatment regimen was similar (12 of 14, 86%, 95% CI, 57% to 98%). Fluorescent in situ hybridization and conventional karyotyping did not identify residual CLL in patients without detectable disease by flow cytometry; however, two patients had preexisting abnormalities considered to be due to the effects of prior chemotherapy on the myeloid lineage, and one had a persistent constitutional translocation. Twelve patients who cleared marrow by flow cytometry after Cy plus Flu and # 2 3 10 6 CAR-T cells/kg also had an identified clonal malignant IGH sequence in CLL cells, and seven of these patients (58%) had no detectable malignant IGH sequences in marrow obtained 4 weeks after CAR-T cell infusion.
Complete Remissions After a Second Cycle of Lymphodepletion and CAR-T Cells
Six patients with persistent or relapsed disease after 1 cycle of lymphodepletion and CAR-T cell infusion had a second cycle of lymphodepletion and CAR-T cells at the same (n = 1) or a 10-fold higher dose (n = 5). Four of six patients developed CRS (two grade $ 3), and one developed reversible neurologic toxicity (grade 3) after the second CAR-T cell infusion. Two patients achieved CR (by PET-CT criteria), and residual CLL was not detected by bone marrow flow cytometry and IGH sequencing.
Factors Correlating With the Clinical Response to CAR-T Cells
We investigated the factors associated with antitumor efficacy of CAR-T cell therapy. Peak CD4 + /EGFRt + and, most notably, CD8 + /EGFRt + CAR-T cell counts were higher in patients who cleared marrow by flow cytometry compared with those who failed to eliminate CLL from marrow ( Fig 3C) and were higher in those who achieved CR by flow and had no malignant IGH sequences detected in marrow compared with those who had CR by flow with residual malignant IGH sequences (Fig 3D) . Probability curves demonstrated a window where peak CD4 + /EGFRt + and CD8 + /EGFRt + CAR-T cell numbers that correlate with a high probability of marrow clearance were associated with an acceptable risk of grade $ 2 neurotoxicity (Fig 3E-F) .
Antitumor activity was seen in a subset of patients with large lymph node burdens (Fig 3G) , including those with Richter's transformation; however, patients with higher lymph node bulk were less likely to respond to CAR-T cells (CR v PR v no response [NR] by IWCLL; P = .098), as were those with fewer prior therapies (CR and/or PR v NR by IWCLL; median, 5.5 v four; P = .04). This suggests that bulky and aggressive nodal disease might be less amenable to CAR-T cell therapy. Although the relationship between the peak CAR-T cell count in blood and the probability of a response in lymph nodes was less robust than that noted for marrow (Fig 3E-F) , higher peak CD3 + /EGFRt + CAR-T cell counts in blood were associated with reduced risk of disease progression and death in high-risk patients with CLL (hazard ratio, 0.56; 95% CI, 0.34 to 0.93; P = .025). One patient with robust CAR-T expansion experienced failure to clear marrow because of the outgrowth of CD19-negative disease (Fig 3H) . No other patients developed CD19-negative disease.
IGH Sequencing Identifies Patients With Durable PFS and OS
A subset of patients who achieved PR by IWCLL at initial restaging had no FDG-avid disease by PET-CT criteria (four of five) and/or had no detectable malignant IGH sequence in marrow (four of six). Further evidence that IWCLL criteria might underestimate the depth of response achieved with CAR-T cells was suggested by the equivalent PFS in patients who achieved PR or CR and ongoing tumor regression after initial restaging in one patient. We analyzed the survival of patients who cleared marrow by flow cytometry in relation to the presence or absence of malignant IGH sequences in marrow 4 weeks after CAR-T cell infusion. Independent of the IWCLL response, patients who were negative for malignant IGH sequences had better PFS compared with those with persistent malignant IGH sequences (Fig 4A and 4B) . Median OS was not reached in either group. The positive effect of marrow clearance by IGH sequencing on outcome was also observed when the analysis was restricted to PFS in patients who responded (CR or PR) by IWCLL criteria (P = .063; median PFS for detectable malignant IGH copies, 8.5 months; median PFS for no detectable malignant IGH copies, not reached).
DISCUSSION
Patients with relapsed and/or refractory CLL with complex cytogenetics and/or del17(p13.1) after prior ibrutinib therapy have a short expected survival. [1] [2] [3] 7, 8 In this study, we treated 24 such patients with CLL with lymphodepletion chemotherapy and CD19-targeted CAR-T cells. We observed a high rate of elimination of CLL from marrow and lymph node response after CAR-T cell therapy. Approximately half of the patients who were evaluated by IGH sequencing to detect residual tumor in marrow lacked jco.org detectable malignant IGH copies. Absence of detectable malignant IGH sequences after conventional therapies for CLL is associated with a lower risk of relapse, but is infrequent. 23 Achieving a malignant IGH-negative status after CAR-T cells in our study correlated better with superior PFS than CR by IWCLL CT criteria, which requires that all lymph nodes be # 15 mm. These data indicate that early restaging by tumor size criteria alone, 4 weeks after CAR-T cell administration, may not be the optimal determinant of prognosis, as suggested after immune checkpoint blockade in other malignancies.
24,25 Additional studies will be required to determine whether strategies such as IGH sequencing, PET imaging, or delayed restaging after CAR-T cell immunotherapy of CLL can identify patients who might benefit from additional CAR-T cell infusions to improve outcomes. In this study, two of six patients who received a second CAR-T cell infusion achieved CR by PET imaging and IGH deep sequencing.
Although bone marrow disease was highly responsive to CAR-T cells, complete elimination of bulky nodal disease was less common, suggesting the malignant lymph node environment may impair CAR-T cell infiltration and/or function. The nodal and molecular CR rate in advanced CLL might be improved if CAR-T cell immunotherapy is delivered when ibrutinib-induced mobilization of lymph node disease into blood and/or marrow is still effective and before development of bulky lymphadenopathy. Such a strategy might be used by monitoring patients receiving ibrutinib for increasing prevalence of ibrutinib-resistance mutations. We detected BTK and PLCG2 mutations in 47% of patients who experienced disease progression receiving ibrutinib, which is lower than results reported by Woyach et al, 26 likely due to the inclusion in our study of a higher proportion of patients who had experienced early treatment failure while receiving ibrutinib and those with Richter's transformation, and the absence of B cell selection in the ibrutinib-resistance mutation assay. 26 The incidence of serious toxicity after CAR-T cell administration was low. One patient died with CRS and neurotoxicity, illustrating the importance of understanding the pathogenesis of neurotoxicity and evaluating intervention strategies. Our previous report in which CD19 CAR-T cells were administered to patients with ALL found that tumor burden is associated with robust CAR-T cell expansion, CRS, and neurotoxicity, and similar associations were observed in this study in patients with CLL. Thus, modifying CAR-T cell dose in relation to tumor burden may further improve outcomes in CLL. Furthermore, our identification of cytokines whose levels early after CAR-T cell infusion predicted severe toxicity will facilitate the study of pre-emptive therapy to mitigate toxicity.
In conclusion, CD19 CAR-T cells are highly effective with manageable toxicity in patients with high-risk CLL, including those who are ibrutinib refractory. This approach can achieve sustained molecular remissions and improve the poor prognosis of ibrutinibrefractory CLL. Future studies in patients who are likely to become refractory to ibrutinib on the basis of high-risk cytogenetics or early detection of mutations before relapse that confer ibrutinib resistance are warranted. jco.org
